SMU-L11 is a specific TLR7 agonist (EC50=0.024 µM) that recruits the MyD88 adaptor protein, activating downstream NF-kappaB and MAPK signaling pathways. In mouse models, SMU-L11 significantly enhances immune cell activation and boosts CD4+ T and CD8+ T cell proliferation, leading to direct tumor cell destruction and inhibition of tumor growth. This compound has applications in cancer research and potential in studying immune system disorders.
Formel:
C19H24N4O
Target-Kategorie:
NF-kappaB|||MAPK|||TLR
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
